An open-label study of AZD0120 in adults with multiple sclerosis

Trial Identifier: D831DC00001
Sponsor: AstraZeneca
Start Date: December 2025
Primary Completion Date: December 2028
Study Completion Date: December 2028
Condition: Multiple Sclerosis (MS)

Available Languages

For questions about your Trial Results Summary, please see Sponsor contact section within your Trial Results Summary.

No documents have been posted yet.

Trial Locations

Country Location
AU Liverpool, AU, 2170
AU Melbourne, AU, 3000
AU Melbourne, AU, 3004
AU Waratah, AU, 2298
CA, QC Montréal, QC, CA, H3A 1A1
DE Leipzig, DE, 04103
DE Magdeburg, DE, 39120
DE Würzburg, DE, DE-97072
GB Cambridge, GB, CB2 2QQ
GB London, GB, SE5 9RS
US, CO Aurora, CO, US, 80045
US, DC Washington, DC, US, 20007
US, MO Saint Louis, MO, US, 63110
US, NY New York, NY, US, 10032
US, NY New York, NY, US, 10016
US, OH Cleveland, OH, US, 44195
US, WA Seattle, WA, US, 98104
US, WI Milwaukee, WI, US, 53226